🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

A Prospective Cohort Study on Drug-induced Liver Injury in China（DILI-P）

Recruitingn/aAges any - anyAllDrug Induced Liver Disease Study Group
NCT02961413 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

This is a multi-center, prospective, non-interventional cohort study . Its primary objectives are: 1. assess DILI patients' clinical characteristics, disease progression and influencing factors in clinical practice; 2. learn about suspected drug caused DILI,rechallenging, liver biochemical abnormalities mode, etc.

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: * Diagnosis of DILI patients with various types and severity according to the 2015 version of the Chinese DILI treatment guidelines * RUCAM ≥6, or RUCAM between 3-5 is required by the three experts determined that the drug-induced liver injury * patient can provide informed consent form Exclusion Criteria: * non-drug-induced liver injury
💊

What it tests

  • Not listed
📍

Where

1 site
Renji hospital
Shanghai, China
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy